On 9 July 2001, orphan designation (EU/3/01/048) was granted by the European Commission to Elan Pharma International Ltd, Ireland, for ziconotide (intraspinal use) for the treatment of chronic pain requiring intraspinal analgesia.
The sponsorship was transferred to Eisai Limited, United Kingdom, in September 2006.For administrative updates: choose or delete if not applicable.
Ziconotide (intraspinal use) has been authorised in the EU as Prialt since 21 February 2005.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
Ziconotide (intraspinal use)
|Disease / condition||
Treatment of chronic pain requiring intraspinal analgesia
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.